{"id":4928,"date":"2019-05-01T15:15:24","date_gmt":"2019-05-01T09:45:24","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4928"},"modified":"2025-05-08T11:57:11","modified_gmt":"2025-05-08T06:27:11","slug":"european-commission-gives-nod-to-zynquista-for-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes","title":{"rendered":"European Commission gives a nod to Zynquista for type 1 diabetes in adults"},"content":{"rendered":"\n<p class=\"has-drop-cap\">The<strong> European Commission<\/strong> approved Zynquista (sotagliflozin) as a new treatment for people with type 1 <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market\">diabetes<\/a><\/strong>. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-kidney-disease-market-insight-epidemiology-and-market-forecast\">kidneys <\/a><\/strong>absorb and glucose that will result in better diabetes control. <br><strong>Sanofi <\/strong>is collaborating the drug with <strong>Lexicon Pharmaceuticals.<\/strong> It has been designed for adults who have a body mass index of <strong>27 kg\/m2 <\/strong>and struggle to keep control of their blood sugar levels.<br> A slew of clinical studies was performed on <strong>3,000 people<\/strong>, and the results showed Zynquista helped in decreasing average blood sugar levels, body weight, and blood pressure and improved time within the target blood glucose range.<br><strong>Dr John Reed, Sanofi&#8217;s global head of research and development <\/strong>apprised the dual mechanism of action of Zynquista. The drug proffers significant treatment benefits for adults with type 1 <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-nephropathy-market\">diabetes <\/a><\/strong>that is, decreasing blood sugar reabsorption in the kidneys through SGLT-2 inhibition and deferring dietary sugar absorption via local SGLT-1 inhibition in the intestinal tract. <br> The European thumbs up Zynquista that trail an approval of <strong>dapagliflozin <\/strong>for type 1 diabetes in February. Dapagliflozin, marketed as <strong>Forxiga<\/strong>, became the first oral medication to get European support for treatment in adults with type 1 diabetes. Dapagliflozin comes into use when insulin solely does not provide adequate control of blood <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/sodium-dependent-glucose-transporter-1-sglt1-inhibitor-pipeline-insight\">glucose<\/a><\/strong>. Forxiga (dapagliflozin) in an SGLT-2 inhibitor medication.<br>Sotagliflozin indicated that it could decrease the glycemic variability in people. Diabetes experts are progressively accentuating time in range as a vital measure than glycated haemoglobin.<\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">&#8220;A plethora of people living with type 1 diabetes who are obese, the drug- Zynquista will proffer a new treatment option. The physicians can now reckon in combination with insulin therapy for suitable patients.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating the drug with Lexicon Pharmaceuticals. It has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4931,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[3680,3676,3679,3681,3677,533,3682,3678,3660],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-4928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-dapagliflozin","tag-dr-john-reed","tag-european-commission","tag-forxiga","tag-lexicon-pharmaceuticals","tag-sanofi","tag-sglt-1-and-sglt-2-proteins","tag-sotagliflozin","tag-zynquista","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Type 1 diabetes Market Trends and Analysis | DelveInsight<\/title>\n<meta name=\"description\" content=\"The European Commission approved sotagliflozin as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents.......\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 1 diabetes Market Trends and Analysis | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The European Commission approved sotagliflozin as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents.......\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-01T09:45:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Type 1 diabetes Market Trends and Analysis | DelveInsight","description":"The European Commission approved sotagliflozin as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents.......","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes","og_locale":"en_US","og_type":"article","og_title":"Type 1 diabetes Market Trends and Analysis | DelveInsight","og_description":"The European Commission approved sotagliflozin as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents.......","og_url":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-01T09:45:24+00:00","article_modified_time":"2025-05-08T06:27:11+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes","url":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes","name":"Type 1 diabetes Market Trends and Analysis | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog.png","datePublished":"2019-05-01T09:45:24+00:00","dateModified":"2025-05-08T06:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The European Commission approved sotagliflozin as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents.......","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/european-commission-gives-nod-to-zynquista-for-type-1-diabetes#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog.png","width":647,"height":345,"caption":"Type 1 diabetes"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09024006\/for-blog-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">dapagliflozin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Dr John Reed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">European Commission<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Forxiga<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Lexicon Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">SGLT-1 and SGLT-2 proteins<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">sotagliflozin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Zynquista<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">dapagliflozin<\/span>","<span class=\"advgb-post-tax-term\">Dr John Reed<\/span>","<span class=\"advgb-post-tax-term\">European Commission<\/span>","<span class=\"advgb-post-tax-term\">Forxiga<\/span>","<span class=\"advgb-post-tax-term\">Lexicon Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">SGLT-1 and SGLT-2 proteins<\/span>","<span class=\"advgb-post-tax-term\">sotagliflozin<\/span>","<span class=\"advgb-post-tax-term\">Zynquista<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on May 1, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on May 1, 2019 3:15 pm","modified":"Updated on May 8, 2025 11:57 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4928"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4928\/revisions"}],"predecessor-version":[{"id":31893,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4928\/revisions\/31893"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4931"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4928"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4928"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}